8-K: ADC Therapeutics Secures $60M Private Placement, Boosts ZYNLONTA Expansion

ADC Therapeutics SA announced a $60 million private placement and preliminary Q3 2025 financial results, alongside promising clinical data for ZYNLONTA in various lymphoma indications.

Summary

• ADC Therapeutics SA entered into securities purchase agreements for a $60.0 million private placement with institutional investors, including TCGX and Redmile Group.
• The private placement involves the sale of 11,250,000 common shares at $4.00 per share and pre-funded warrants to purchase 3,846,153 common shares at $3.90 per pre-funded warrant (exercise price CHF 0.08).
• Net proceeds from the financing are estimated at $57.6 million, intended for ZYNLONTA commercial expansion, balance sheet strengthening, working capital, and general corporate purposes.
• Preliminary net product revenues from ZYNLONTA sales for Q3 2025 are approximately $15.8 million.
• Cash and cash equivalents totaled $234.7 million as of September 30, 2025, which would increase to approximately $292.3 million pro forma for the private placement.
• The LOTIS-5 Phase 3 trial (ZYNLONTA + rituximab in 2L+ DLBCL) has completed enrollment, with topline data expected in 1H 2026.
• The LOTIS-7 Phase 1b trial (ZYNLONTA + glofitamab in r/r LBCL) showed an 86.7% complete response rate (CR) in efficacy-evaluable patients (N=30) as of April 14, 2025.
• Investigator-initiated trials (IITs) for ZYNLONTA demonstrated a 69.2% CR rate in relapsed/refractory Marginal Zone Lymphoma (r/r MZL) and an 83.6% CR rate in relapsed/refractory Follicular Lymphoma (r/r FL) in efficacy-evaluable patients.
• The company is advancing IND-enabling activities for a next-generation PSMA-targeting ADC with a novel exatecan-based payload.

Sentiment

Score: 8

Explanation: The filing presents a strong positive outlook due to a substantial capital raise that significantly improves the company's financial position and extends its cash runway. This is coupled with highly encouraging clinical data for ZYNLONTA in multiple indications, particularly the impressive complete response rates in combination therapies and IITs, which suggest significant future growth potential and competitive advantages in key markets. While preliminary financial results are noted, the overall strategic and clinical advancements are very favorable.

Positives

• Successfully secured a $60.0 million private placement, significantly strengthening the balance sheet and extending the cash runway into 2028.
• Preliminary Q3 2025 ZYNLONTA net product revenues of $15.8 million indicate continued commercial activity.
• LOTIS-7 Phase 1b data for ZYNLONTA + glofitamab shows a high complete response rate of 86.7% in r/r LBCL, suggesting strong efficacy potential.
• Investigator-initiated trials for ZYNLONTA in r/r MZL (69.2% CR) and r/r FL (83.6% CR) demonstrate promising efficacy in indolent lymphomas.
• The company is advancing a new PSMA-targeting ADC, indicating a robust pipeline beyond ZYNLONTA.

Negatives

• The financial figures for Q3 2025 are preliminary and unaudited, subject to potential material differences in final SEC filings.
• Continued approval for ZYNLONTA's current indication is contingent upon verification of clinical benefit in a confirmatory trial.
• The private placement involves the sale of new equity, leading to dilution for existing shareholders.

Risks

• The success of the company's strategic restructuring plan and potential changes in associated costs, including workforce reduction and facility closure.
• The cash runway into 2028 assumes the use of minimum liquidity required under loan agreement covenants.
• Future LOTIS-7 clinical trial results may not be consistent with or may differ from previously presented data.
• The timing of PFS events for LOTIS-5 and the results of the trial, which are crucial for full FDA approval.
• The company's ability to grow ZYNLONTA revenue in the United States and its partners' ability to commercialize it in foreign markets.
• The timing and results of the company's or its partners' research and development projects or clinical trials, including LOTIS-5, LOTIS-7, and early pre-clinical research for the PSMA-targeting ADC.
• The timing and results of investigator-initiated trials, including those studying FL and MZL, and their potential regulatory and/or compendia strategy.
• The timing and outcome of regulatory submissions for the company's products or product candidates and actions by the FDA or foreign regulatory authorities.
• The company's indebtedness, including facilities with Healthcare Royalty Management, Blue Owl, and Oaktree, and the restrictions imposed by such indebtedness, as well as the ability to comply with terms and repay debt.
• The company's ability to obtain financial and other resources for its research, development, clinical, and commercial activities.
• Uncertainties of international trade policies, including tariffs, sanctions, and trade barriers, and their potential impact on the business.

Future Outlook

The company anticipates a potential relaunch of ZYNLONTA in 2027 and expects its cash runway to extend into 2028, bolstered by the recent financing. Management looks forward to upcoming data catalysts in late 2025 and throughout 2026, aiming to expand ZYNLONTA into earlier lines of therapy and new indications. The company is also advancing its PSMA-targeting ADC towards IND-enabling activities.

Management Comments

• "This financing enhances our ability to prepare for and execute the potential relaunch of ZYNLONTA in 2027 and further strengthens our balance sheet relative to our previously disclosed cash runway into 2028."
• "We believe we are well-positioned to accelerate our trajectory towards long-term sustainable growth for our company."
• "We look forward to upcoming data catalysts later this year and throughout 2026."

Industry Context

The announcement positions ADC Therapeutics to potentially disrupt the relapsed/refractory DLBCL market and expand into indolent lymphomas. ZYNLONTA's combination therapies, particularly with bispecifics like glofitamab, show complete response rates that rival or exceed current CAR T-cell therapies and other bispecific combinations, offering a potentially more accessible treatment option. The focus on both complex and broadly accessible therapy segments indicates a comprehensive strategy to capture market share in a competitive landscape, while the PSMA-targeting ADC development signals diversification into solid tumors.

Comparison to Industry Standards

• ZYNLONTA monotherapy (LOTIS-2) in 3L+ DLBCL achieved a 25% Complete Response (CR) rate, comparable to R-GEMOX (25% CR) but generally lower than CAR T-cell therapies (e.g., Yescarta 65% CR, Breyanzi 66% CR) and some bispecifics.
• ZYNLONTA + rituximab (LOTIS-5 safety run-in) in 2L+ DLBCL showed a 50% CR rate, positioning it as a strong contender among broadly accessible therapies (ADCs, mAbs, chemo/other) which typically range from 37-45% CR (e.g., Brentuximab + R2 45% CR, Polatuzumab + BR 40% CR, Tafasitamab + Lenalidomide 37% CR).
• ZYNLONTA + glofitamab (LOTIS-7) in r/r LBCL achieved an 86.7% CR rate, which is notably higher than CAR T-cell therapies (e.g., Yescarta 65% CR, Breyanzi 66% CR) and other bispecific combinations (e.g., Glofit + GEMOX 59% CR, Mosunetuzumab + Polatuzumab 58% CR, Epcoritamab + GEMOX 61% CR), suggesting a potentially leading efficacy profile in the complex therapy segment.
• In r/r MZL, ZYNLONTA IIT demonstrated a 69.2% CR rate, significantly higher than other approved therapies like Acalabrutinib (13% CR) and Lenalidomide + Rituximab (29% CR), and also higher than Zanubrutinib (26% CR) and Pirtobrutinib (3% CR).
• In r/r FL, ZYNLONTA + Rituximab IIT achieved an 83.6% CR rate, which is competitive with or superior to many 2L+ and 3L+ FDA-approved/NCCN preferred regimens, including Tafasitamab + Rituximab (49% CR), Bendamustine + Obinutuzumab (16% CR), and even some CAR T-cell therapies like Axi-cel (79% CR) and Tisa-cel (86% CR), though slightly below Liso-cel (94% CR).

Stakeholder Impact

• **Shareholders:** Experience dilution from the private placement but benefit from a significantly strengthened balance sheet, extended cash runway, and reduced financial risk. Positive clinical data could drive future share price appreciation.
• **Patients:** Potential for new, highly effective treatment options for relapsed/refractory large B-cell lymphoma, follicular lymphoma, and marginal zone lymphoma, especially with ZYNLONTA combination therapies showing high complete response rates.
• **Employees:** Improved financial stability and continued investment in commercial expansion and R&D may lead to greater job security and growth opportunities.
• **Creditors:** A stronger balance sheet and extended cash runway enhance the company's ability to meet its debt obligations, reducing credit risk.

Next Steps

• Closing of the $60.0 million private placement on October 27, 2025.
• File a registration statement within 30 business days to register the resale of common shares and warrant shares from the private placement.
• Provide topline data for the LOTIS-5 Phase 3 trial in 1H 2026, after the prespecified number of PFS events is reached.
• Submit a sBLA for LOTIS-5 and pursue potential approval following topline data.
• Continue dose expansion for LOTIS-7 (ZYNLONTA + glofitamab) to 100 patients at the 150 g/kg dose.
• Expand investigator-initiated trials for ZYNLONTA in r/r MZL and r/r FL to additional cancer research centers and increase target enrollment.
• Assess regulatory and compendia pathways for ZYNLONTA in r/r MZL and r/r FL as sufficient data become available.
• Advance IND-enabling activities for the PSMA-targeting ADC candidate.
• Seek research collaborations for the PSMA-targeting ADC.

Key Dates

Recommendation

The $60 million private placement significantly de-risks ADC Therapeutics' financial position, extending its cash runway into 2028 and providing capital for ZYNLONTA's commercial expansion and pipeline development. The preliminary Q3 2025 ZYNLONTA revenue is positive, and the clinical data for ZYNLONTA, particularly the 86.7% CR rate in LOTIS-7 and strong results in IITs for FL and MZL, are highly compelling and suggest a strong competitive profile against existing therapies, including CAR-T. These clinical advancements, combined with a strengthened balance sheet, position the company for substantial long-term growth and potential market share gains in lucrative oncology segments. The stock appears undervalued given these positive developments and future catalysts.

Keywords

ADC Therapeutics, ADCT, ZYNLONTA, Loncastuximab Tesirine, Antibody Drug Conjugate, Private Placement, PIPE Financing, Relapsed Refractory Large B-cell Lymphoma, DLBCL, Follicular Lymphoma, FL, Marginal Zone Lymphoma, MZL, Clinical Trials, LOTIS-5, LOTIS-7, PSMA, Oncology, Hematologic Malignancies, Biotechnology, Pharmaceuticals